Jason Romancik, MD
Hematology & Oncology · Atlanta, GANPI 1558743187
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,426 of the $40,183 with a category attached, or 63.3%. 19 manufacturers reported payments, led by ADC Therapeutics America, Inc. at 59.5% of the total. 2025 is the largest year on record at $21,066, 4.5 times the $4,717 reported in 2022.
Across 68 payments — averaging $590.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$24K
- E.r. Squibb & Sons, L.L.C.$8K
- AstraZeneca$4K
- Gilead$3K
- Bristol Myers Squibb$679
- Daiichi Sankyo Inc.$181
- plus $669 from 13 others
Across 63 payments — averaging $24,003 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$1.2M
- Genentech, Inc.$142K
- AbbVie$85K
- Gilead$68K
- Pfizer$34K
- Daiichi Sankyo Inc.$18K
What the payments were for
- Consulting fees$25,42663%
- Speaking & faculty fees$10,50026%
- Travel & lodging$2,0045%
- Food & beverage$2,2536%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 22 | $23,915 |
| E.r. Squibb & Sons, L.L.C. | 1 | $8,118 |
| AstraZeneca | 3 | $4,035 |
| Gilead(2 entities) | 2 | $2,586 |
| Bristol Myers Squibb | 16 | $679 |
| Daiichi Sankyo Inc. | 5 | $181 |
| Novartis | 5 | $136 |
| Beigene USA, Inc. | 3 | $106 |
| Legend Biotech USA Inc. | 1 | $98 |
| TG Therapeutics, Inc. | 1 | $80 |
| Amgen | 1 | $48 |
| Sanofi | 1 | $44 |
| Genentech USA, Inc. | 1 | $37 |
| Astellas Pharma US Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Merck | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Invivyd Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,183 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 36 | $521,595 |
| CalquenceAcalabrutinib Maleate | 34 | $486,822 |
| PromactaEltrombopag Olamine | 22 | $267,831 |
| JakafiRuxolitinib Phosphate | 12 | $175,890 |
| CresembaIsavuconazonium Sulfate | 11 | $68,113 |
| VemlidyTenofovir Alafenamide | 13 | $18,042 |
| EliquisApixaban | 27 | $16,936 |
| ValacyclovirValacyclovir Hcl | 107 | $4,168 |
| Entecavir | 14 | $284 |
| Gabapentin | 17 | $211 |
| Oxycodone Hcl | 23 | $194 |
| Trazodone Hcl | 20 | $187 |
| Ondansetron Hcl | 18 | $118 |
| Prochlorperazine Maleate | 16 | $112 |
| Prednisone | 34 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $106 | $521,59536 claims |
| AstraZenecaCalquence | $4,035 | $486,82234 claims |
| NovartisPromacta | $136 | $267,83122 claims |
| Astellas Pharma US IncCresemba | $23 | $68,11311 claims |
| GileadVemlidy | $2,586 | $18,04213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Atlanta
- Ticiana LealAtlanta$450K
- Ajay NookaAtlanta$222K
- Rodolfo BordoniAtlanta$159K
- Mehmet BilenAtlanta$150K
- Olatunji AleseAtlanta$137K
- Gina D AmatoAtlanta$97K
- Otis BrawleyAtlanta$89K
- Conor SteuerAtlanta$86K
- Fuad El RassiAtlanta$84K
- Jonathon CohenAtlanta$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.